The 222 references in paper A. Smirnov V., I. Trofimenko I., V. Sipovskiy G., А. Смирнов В., И. Трофименко И., В. Сиповский Г. (2013) “БОЛЕЗНЬ МИНИМАЛЬНЫХ ИЗМЕНЕНИЙ У ВЗРОСЛЫХ // MINIMAL CHANGE DISEASE IN ADULTS” / spz:neicon:nefr:y:2013:i:6:p:9-36

1
Coggis CH. Minimal change nephrosis in adults. In: Zurukzoglu W, ed. Treatable and Preventable Glomerular Disease, Karger, Basel, Switzerland, 1981. 336-344. Proceedings of the 8th International Congress of Nephrology
(check this in PDF content)
2
Lewis EJ. Management of the nephrotic syndrome in adults. In: Caeron JS, Glassock RJ, eds. The Nephrotic Syndrome. Dekker, New York, 1988. 461-521
(check this in PDF content)
3
Cameron, JS Hick J. The origins and development of the concept of a ‘nephrotic syndrome’ Am J Nephrol 2002; 22: 240247
(check this in PDF content)
4
Volhard F, Fahr T. Die Brighsche Nierenkrankheit, Klinik, Pathologie und Atlas. J.Springer, Berlin, 1914
(check this in PDF content)
5
Fogazzi G B, E Ritz Novel classification of glomerulonephritis in the monograph of Franz Volhard and Theodor Fahr. Nephrol Dia Transplant 1998; 13(11): 2965-2967
(check this in PDF content)
6
Luft FC, Dietz R Franz. Volhard in historical perspective. Hypertension 1993; 22(2):m253-256
(check this in PDF content)
7
Серов ВВ, Варшавский ВА Что называть гломерулонефритом: спорные вопросы классификации. Арх пат 1987; (1): 67-75
(check this in PDF content)
8
Варшавский ВА, Проскурнева ЕП, Гасанов АБ, и др. Об уточнении клинико-морфологической классификации хронического гломерулонефрита. Нефрология и диализ 1999; 1:(2-3) : 100–106
(check this in PDF content)
9
http://www.icd10data.com/ICD10CM/Codes/N00-N99,
(check this in PDF content)
10
Barisoni L, Schnaper HW, Kopp JB. A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol 2007; 2(3): 529-542
(check this in PDF content)
11
Wang SX, Zhang YK, Zhao MH, Zou WZ. Ultrastructural features and expression of cytoskeleton proteins of podocyte from patients with minimal change disease and focal segmental glomerulosclerosis. Shi SF Ren Fail 2008; 30(5): 477-483
(check this in PDF content)
12
Kavoura E, Gakiopoulou H, Paraskevakou H, et al. Immunohistochemical evaluation of podocalyxin expression in glomerulopathies associated with nephrotic syndrome. Hum Pathol 2011; 42(2): 227-235
(check this in PDF content)
13
Смирнов АВ. Лечение гломерулопатий циклоспорином. Правильный подход с неверным обоснованием. Нефрология 2010; 14(4): 9-22
(check this in PDF content)
14
Primary nephritic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A report of the International Study of kidney Disease in children. Kidney Int 1981;20:765-71. [No authors listed]-
(check this in PDF content)
15
Begum A, Rahman H, Hossain MM, at al. Histological variant of nephrotic syndrome with atypical presentation in children. Mymensingh Med J 2009; 18(1) 42-46
(check this in PDF content)
16
Maruyama M, Toyoda M, Umezono T, et al Clinical significance of IgM deposition in the mesangium and mesangial hypercellularity in adult minimal change nephrotic syndrome. Nihon Jinzo Gakkai Shi 2006; 48(1): 14-21
(check this in PDF content)
17
D’Agati VD, Jannette JCh, Silva FG. Non-Neoplastic kidney Diseases. Chapter 5: Minimal Change Disease ARP Press, Wasington, 2005; 105-125
(check this in PDF content)
18
Zhou XJ, Laszik Z, Nadasdy T, D’Agati V, Silva FG et al. Silva’s Diagnostic Renal Pathology. Chapter 4:Glomerular Disease associated with nephrotic syndrome and proteinuria. Cambridge University Press 2009; 79-127
(check this in PDF content)
19
Tsukada M, Honda K, Nitta K, et al. [Incidental mesangial IgA deposition in minimal change nephrotic syndrome(MCNS)]. Nippon Jinzo Gakkai Shi 2003; 45(7): 681-688
(check this in PDF content)
20
Choi J, Jeong HJ, Lee HY, et al. Significance of mesangial IgA deposition in minimal change nephrotic syndrome: a study of 60 cases. Yonsei Med J 1990; 31(3): 258-263
(check this in PDF content)
21
Westhoff TH, Waldherr R, Loddenkemper C, at al. Mesangial IgA deposition in minimal change nephritic syndrome : coincide in different entities or variant of minimal change disease. Clin.Nephrol 2006; 65(3): 203-207
(check this in PDF content)
22
Soma J, Saito T, Sato H, et al. [Minimal change nephrotic syndrome with predominant mesangial IgA deposits: clinicopathological study]. Nippon Jinzo Gakkai Shi 1991; 33(2): 153-159
(check this in PDF content)
23
Kerjaschki D. Dysfunctions of cell biological mechanisms of visceral epithelial cell (podocytes) in glomerular diseases. Kidney Int 1994; 45: 300–313
(check this in PDF content)
24
Chuang PY, He JC. Signaling in regulation of podocyte phenotypes. Nephron Physiol 2009; 111 (2): 9-15
(check this in PDF content)
25
Nakamura T, Ushiyama C, Suzuki S, et al. The urinary podocyte as a marker for the differential diagnosis of idiopathic focal glomerulosclerosis and minimal-change nephrotic syndrome. Am J Nephrol 2000; 20(3): 175-179
(check this in PDF content)
26
Shi SF, Wang SX, Zhang YK, et al. Ultrastructural features and expression of cytoskeleton proteins of podocyte from patients with minimal change disease and focal segmental glomerulosclerosis. Ren Fail 2008; 30(5): 477-483
(check this in PDF content)
27
Berg JG, van den Bergh Weerman MA, Assmann KJ, et al. Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int 2004; 66(5): 1901-1906
(check this in PDF content)
28
Deegens JK, Dijkman HB, Borm GF, et al. Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney Int 2008; 74(12): 1568-1576
(check this in PDF content)
29
Coppo R, Ponticelli C. Minimal change nephropathy. In: Ponticelli C, Glassock R.F., eds. Treatment of primary glomerulonephritis. 2-nd ed. Oxford university press, N-Y, 2009, 179-213
(check this in PDF content)
30
Audard V, Lang P, Sahali D. [Minimal change nephrotic syndrome : new insights into disease pathogenesis]. Med Sci (Paris). 2008; 24(10): 853-858
(check this in PDF content)
31
Morales-Ruiz M, Fulton D, Sowa G, et al. Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. Circ Res 2000; 86(8): 892-896
(check this in PDF content)
32
Sung, SH, Ziyadeh FN, Wang A, et al. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 2006; 17(11): 3093-3104
(check this in PDF content)
33
McCarthy E T, Sharma M, Savin VJ. Circulating Permeability Factors in Idiopathic Nephrotic Syndrome and Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol 2010; 5(11): 2115-2121
(check this in PDF content)
34
Bakker WW, Borghuis T, Harmsen MC, et al.Protease activity of plasma hemopexin. Kidney Int 2005; 68(2), 603–610
(check this in PDF content)
35
Lai KW, Wei CL, Tan LK, et al. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J Am Soc Nephrol 2007; 18(5): 1476–1485
(check this in PDF content)
36
Abdel-Hafez M, Shimada M, Lee PY, et al. Idiopathic nephrotic syndrome and atopy: is there a common link? Am J Kidney Dis 2009; 54(5): 945-953
(check this in PDF content)
37
Pavenstädt H, Kriz W, Kretzler M. Cell Biology of the Glomerular Podocyte Physiol Rev J 2003; 83:253-307
(check this in PDF content)
38
Faul C, Asanuma K, Yanagida-Asanuma E, et al. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends cell biol 2007; 17 (9): 428-437
(check this in PDF content)
39
Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med 2006; 354(13): 1387-1401
(check this in PDF content)
40
Piscione TD, Licht C.Genetics of proteinuria: an overview of gene mutations associated with nonsyndromic proteinuric glomerulopathies. Adv Chronic Kidney Dis 2011; 18(4): 273-289
(check this in PDF content)
41
Saleem MA New developments in steroid-resistant nephrotic syndrome. Pediatr Nephrol 2013;28(5): 699-709
(check this in PDF content)
42
Lahdenkari AT, Kestilä M, Holmberg C, et al Nephrin gene (NPHS1) in patients with minimal change nephrotic syndrome (MCNS). Kidney Int 2004; 65(5): 1856-1863
(check this in PDF content)
43
Shono A, Tsukaguchi H, Kitamura A, et al. Predisposition to relapsing nephrotic syndrome by a nephrin mutation that interferes with assembly of functioning microdomains. Hum Mol Genet 2009; 18(16): 2943-2956
(check this in PDF content)
44
Regele HM, Fillipovic E, Langer B et al. Glomerular expression of dystroglycans is reduced in minimal change nephrosis but not in focal segmental glomerulosclerosis. J Am Soc Nephrol 2000; 11: 403–404
(check this in PDF content)
45
Giannico G, Yang H, Neilson EG, Fogo AB. Dystroglycan in the diagnosis of FSGS. Clin J Am Soc Nephrol 2009; 4(11): 1747-1753
(check this in PDF content)
46
Clement LC, Avila-Casado C, Macé C, et al. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoidsensitive nephrotic syndrome. Nat Med. 2011; 17(1): 117-1122
(check this in PDF content)
47
Reiser J, von Gersdorff G, Loos M, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome J Clin Invest 2004; 113(10): 1390-1397
(check this in PDF content)
48
Garin EH, Mu W, Arthur JM, et al. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int 2010; 78(3): 296-302
(check this in PDF content)
49
Araya C, Diaz L, Wasserfall C et al. T regulatory cell function in idiopathic minimal lesion nephrotic syndrome. Pediatr Nephrol 2009; 24: 1691–1698
(check this in PDF content)
50
Glassock, RJ. Secondary minimal change disease. Nephrol Dial Trans]plant 2003; 18 (Suppl 6):vi52 – vi58
(check this in PDF content)
51
Lien YH, Lai LW. Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis. Nat Rev Nephrol 2011; 7(2): 85-95
(check this in PDF content)
52
Auguet, T, Lorenzo, A, Colomer, E, et al. Recovery of minimal change nephrotic syndrome and acute renal failure in a patient with Renal cell carcinoma. Am J Nephrol 1998; 18: 433-435
(check this in PDF content)
53
Ravnskov U. Glomerular, tubular and interstitial nephritis associated with non-steroidal antiinflammatory drugs. Evidence of a common mechanism. Br J Clin Pharmacol 1999; 47(2): 203-210
(check this in PDF content)
54
Hertig A, Droz D, Lesavre P, et al. SLE and idiopathic nephrotic syndrome: coincidence or not? Am J Kidney Dis 2002; 40(6): 1179-1184
(check this in PDF content)
55
Lewis EJ, Schwartz MM, Korbet SM, Chan TM, eds. Lupus Nephritis, 2nd ed. Oxford Univercity Press, N-Y, 2011, p.325
(check this in PDF content)
56
Alpers CE, Cotran RS Neoplasia and glomerular injury. Kidney Int 1986; 30(4): 465-473
(check this in PDF content)
57
Audard V, Larousserie F, Grimbert P, et al.. Minimal change nephrotic syndrome and classical Hodgkin’s lymphoma: report of 21 cases and review of the literature. Kidney Int 2006; 69(12): 2251-2260
(check this in PDF content)
58
Sayegh J, Boisliveau V, Boyer F, et al. Steroid-resistant minimal change nephrotic syndrome in Waldenstr m macroglobulinemia. Ann Hematol 2013; 92(3): 425-426.
(check this in PDF content)
59
Bacchetta J, Juillard L, Cochat P, Droz JP. Paraneoplastic glomerular diseases and malignancies. Crit Rev Oncol Hematol 2009; 70(1): 39-58
(check this in PDF content)
60
Whelan TV, Hirszel P. Minimal-change nephropathy associated with pancreatic carcinoma. Arch Intern Med 1988; 148(4): 975-976
(check this in PDF content)
61
Meyrier A, Delahousse M, Callard P, Rainfray M. Minimal change nephrotic syndrome revealing solid tumors. Nephron 1992; 61(2): 220-223
(check this in PDF content)
62
Miyajima S, Taguchi Y, Tanaka E, et al. [A case of pulmonary adenocarcinoma accompanied by minimal change nephrotic syndrome, antiphospholipid syndrome and warm-type autoimmune hemolytic anemia]. Nihon Kokyuki Gakkai Zasshi 2006; 44(9):
(check this in PDF content)
63
635.[Article in Japanese] 63. Macanovic M, Peat D. Minimal change nephropathy with adenocarcinoma of breast. J R Soc Med 2000; 93(10): 539
(check this in PDF content)
64
Chan PC, Lau CC, Cheng IK, et al. Minimal change glomerulopathy in two patients after thymectomy. Singapore Med J 1990; 31(1): 46-47
(check this in PDF content)
65
Bacchetta J, Ranchère D, Dijoud F, Droz JP. Mesothelioma of the testis and nephrotic syndrome: a case report. J Med Case Rep 2009; 3: 7248
(check this in PDF content)
66
Aoyama, M, Sugimoto, T, Yokono, T, et al. Minimal-change nephropathy and chronic hepatitis C infection: coincidental or associated? Nephrol Dial Transplant 2007; 22:1479-1480
(check this in PDF content)
67
Stubanus M, Göbel H, Rieg S, et al..Quiz page. Minimal change glomerulonephritis associated with secondary syphilis. Am J Kidney Dis 2007; 49(6): A49-50
(check this in PDF content)
68
Almansori, M, Kovithavongs, T, Qarni, MU. Cyclooxygenase-2 inhibitor-associated minimal-change disease. Clin Nephrol 2005; 63:381-384
(check this in PDF content)
69
Alper AB Jr, Meleg-Smith S, Krane NK. Nephrotic syndrome and interstitial nephritis associated with celecoxib.Am J Kidney Dis 2002; 40(5): 1086-1890.
(check this in PDF content)
70
Sakarcan A, Thomas DB, O’Reilly KP, Richards RW. Lithium-induced nephrotic syndrome in a young pediatric patient. Pediatr Nephrol 2002; 17(4): 290-292
(check this in PDF content)
71
Belghiti D, Patey O, Berry JP, et al. [Lipoid nephrosis of toxic origin. 2 cases]. Presse Med 1986; 15(39): 1953-1955. [Article in French]
(check this in PDF content)
72
Tang HL, Chu KH, Mak YF, et al. Minimal change disease following exposure to mercury-containing skin lightening cream. Hong Kong Med J 2006; 12(4): 316-318
(check this in PDF content)
73
Tang HL, Mak YF, Chu KH, et al. Minimal change disease caused by exposure to mercury-containing skin lightening cream: a report of 4 cases. Clin Nephrol. 2013;7 9(4): 326-334
(check this in PDF content)
74
Mori S, Matsushita Y, Arizono K. Minimal-change nephrotic syndrome associated with isoniazid in anti-tuberculosis chemoprophylaxis for a patient with rheumatoid arthritis. Intern Med 2011; 50(3): 253-257
(check this in PDF content)
75
Takeuchi T, Takegawa M, Ito Y, et al. [Minimal change nephrotic syndrome developing in a rheumatoid arthritis patient under etanercept treatment]. Nihon Rinsho Meneki Gakkai Kaishi 2008; 31(3): 178-182.[Article in Japanese]
(check this in PDF content)
76
Tasic V, Lozanovski VJ, Ristoska-Bojkovska N, et al. Nephrotic syndrome occurring during tiopronin treatment for cystinuria. Eur J Pediatr 2011;v170(2):v247-249
(check this in PDF content)
77
Silva S, Maximino J, Henrique R, et al. Minimal change nephrotic syndrome after stem cell transplantation: a case report and literature review. Journal of Medical Case Reports 2007, 1:121
(check this in PDF content)
78
Troxell ML, Pilapil M, Miklos DB, et al. Renal pathology in hematopoietic cell transplantation recipients. Mod Pathol 2008; 21(4): 396-406
(check this in PDF content)
79
Raml A, Sedlak M, Schmekal B, et al. Spontaneous remission of therapy-resistant minimal change nephritis in an adult woman 12 years after onset of the disease. Wien Med Wochenschr 2006; 156(13-14): 421-425
(check this in PDF content)
80
Colattur SN, Korbet SM. Long-term Outcome of Adult Onset Idiopathic Minimal Change Disease. Saudi J Kidney Dis Transpl 2000; 11(3): 334-344
(check this in PDF content)
81
Cameron JS, Turner DR, Ogg CS, et al. The nephrotic syndrome in adults with minimal change glomerular lesions. Q J Med 1974;43: 461-488
(check this in PDF content)
82
Waldman, M, Crew, RJ, Valeri, A, et al. Adult minimalchange disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2007; 2: 445 –453
(check this in PDF content)
83
Schrier RW: Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy. N Engl J Med 1988; 319: 1065-1076
(check this in PDF content)
84
Schrier RW, Fassett RG. A critique of the overfill hypothesis of sodium and water retention in the nephrotic syndrome. Kidney Int 1998; 53:1111-1117
(check this in PDF content)
85
Zacchia M, Trepiccione F, Morelli F, et al. Nephrotic syndrome: new concepts in the pathophysiology of sodium retention. J Nephrol 2008; 21(6): 836-842
(check this in PDF content)
86
Doucet A, Favre G, Deschênes G. Molecular mechanism of edema formation in nephrotic syndrome: therapeutic implications. Pediatr Nephrol 2007; 22(12):1983-1990
(check this in PDF content)
87
Deschenes G, Gonin S, Zolty E, et al. Increased synthesis and avp unresponsiveness of Na,K-ATPase in collecting duct from nephritic rats. J Am Soc Nephrol 2001; 12: 2241-2252
(check this in PDF content)
88
Besse-Eschmann V, Klisic J, Nief V, et al. Regulation of the proximal tubular sodium/proton exchanger NHE3 in rats with puromycin aminonucleoside (PAN)-induced nephrotic syndrome. J Am Soc Nephrol 2002; 13: 2199-2206
(check this in PDF content)
89
Svenningsen P, Bistrup C, Friis UG, et al. Plasmin in nephrotic urine activates the epithelial sodium channel. J Am Soc Nephrol 2009; 20:299-310
(check this in PDF content)
90
Passero CJ, Hughey RP, Kleyman TR. New role for plasmin in sodium homeostasis. Curr Opin Nephrol Hypertens 2010; 19(1): 13-19
(check this in PDF content)
91
Svenningsen P, Friis UG, Versland JB, et al .Mechanisms of renal NaCl retention in proteinuric disease. Acta Physiol (Oxf) 2013; 207(3):536-545
(check this in PDF content)
92
Lewis DM, Tooke JE, Beaman M, et al. Peripheral microvascular parameters in the nephrotic syndrome. Kidney Int 1998;54(4):1261-1266
(check this in PDF content)
93
Siddall EC, Radhakrishnan J. The pathophysiology of edema formation in the nephrotic syndrome. Kidney Int 2012; 82(6): 635-642
(check this in PDF content)
94
Koomans HA. Pathophysiology of oedema in idiopathic nephrotic syndrome. Nephrol Dial Transplant 2003; 18 Suppl 6: vi30-vi32
(check this in PDF content)
95
Theuns-Valks SD, van Wijk JA, van Heerde M, et al. Abdominal Pain and Vomiting in a Boy With Nephrotic Syndrome. Clin Pediatr (Phila) 2011; 50(5): 470-473
(check this in PDF content)
96
Wang SJ, Tsau YK, Lu FL, Chen CH. Hypovolemia and hypovolemic shock in children with nephrotic syndrome. Acta Paediatr Taiwan 2000; 41(4): 179-183
(check this in PDF content)
97
KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012; 2 (2), 156–180
(check this in PDF content)
98
Sakarcan A, Timmons C, Seikaly M. Reversible idiopathic acute renal failure in children with primary nephritic syndrome. J Pediatr 1994; 125: 723–727
(check this in PDF content)
99
Tavares MB, Chagas de Almeida Mda C, Martins RT, et al . Acute tubular necrosis and renal failure in patients with glomerular disease. Ren Fail 2012; 34(10): 1252-1257
(check this in PDF content)
100
Lowenstein J, Schacht RG, Baldwin DS. Renal failure in minimal change nephrotic syndrome. Am J Med 1981; 70(2): 227-233
(check this in PDF content)
101
Nolasco F, Cameron JS, Heywood EF et al. Adult onset minimal change nephrotic syndrome; a long term follow-up. Kidney Int 1986; 29: 1215-1223
(check this in PDF content)
102
Stellato T, Cappelleri A, Farina M, et al. Severe reversible acute renal failure in idiopathic nephrotic syndrome. J Nephrol 2010; 23(6): 717-724
(check this in PDF content)
103
Morita A, Ishimura E, Tabata T, Shoji et al. Acute renal failure associated with minimal change nephrotic syndrome in an elderly adult. Osaka City Med J 1994; 40(1): 37-42
(check this in PDF content)
104
Cameron MA, Peri U, Rogers TE, Moe OW. Minimal change disease with acute renal failure: a case against the nephrosarca hypothesis. Nephrol Dial Transplant 2004; 19: 2642-2646
(check this in PDF content)
105
Tinawi M, Salinas-Madrigal L, Domoto D Minimal change disease presenting with acute tubular necrosis. Am J Kidney Dis 1995; 25(4): 648-650
(check this in PDF content)
106
Agarwal N, Phadke KD, Garg I, Alexander P Acute renal failure in children with idiopathic nephrotic syndrome. Pediatr Nephrol 2003; 18(12): 1289-1292
(check this in PDF content)
107
Koomans HA Pathophysiology of acute renal failure in idiopatic nephrotic syndrome. Nephrol Dial Transplant 2001; 16(2):221-224
(check this in PDF content)
108
Baek JE, Yang WS, Chang JW, et al. Fatty acid-bearing albumin induces VCAM-1 expression through c-Src kinase-AP-1/ NF-kB pathways: effect of L-carnitine. Kidney Blood Press Res 2010; 33(1): 72-84
(check this in PDF content)
109
Ishola DA Jr, Post JA, van Timmeren MM, et al. Albuminbound fatty acids induce mitochondrial oxidant stress and impair antioxidant responses in proximaltubular cells. Kidney Int 2006; 70(4): 724-731
(check this in PDF content)
110
Guash A, Myers B. Determinants of glomerular hypofiltration in nephrotic patients with minimal changes nephropathy. J Am Soc Nephrol 1994; 4: 1571-1581
(check this in PDF content)
111
Drummond MC, Kristal B, Myers BD, Deen WM. Structural basis for reduced filtration capacity in nephrotic syndrome. J Clin Invest 1994; 4: 187-1195
(check this in PDF content)
112
Vande Walle JG, Mauel R, Raes A, et al. ARF in children with minimal changes nephritic syndrome may be related to functional changes of the glomerular basal membrane. Am J Kidney Dis 2004; 43: 399- 404
(check this in PDF content)
113
Yalavarthy R, Smith ML, Edelstein C. Acute kidney injury complicating minimal change disease: the case for careful use of diuretics and angiotensin-converting enzyme inhibitors. Nephrology (Carlton) 2007; 12(5): 529-531
(check this in PDF content)
114
Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol 2012; 7(3): 513-552
(check this in PDF content)
115
Llach, F, Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome.Kidney Int 1985, 28: 429-439
(check this in PDF content)
116
Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol 2007; 18(8): 2221-2225
(check this in PDF content)
117
Mahmoodi BK, ten Kate MK, Waanders F, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation 2008; 117(2): 224-230
(check this in PDF content)
118
Lee JK, Baek MS, Mok YM, et al. Successfully treated femoral artery thrombosis in a patient with minimal change nephrotic syndrome. Chonnam Med J 2013 Apr; 49(1): 50-53
(check this in PDF content)
119
Palmer SC, Nand K, Strippoli GF. Interventions for minimal change disease in adults with nephrotic syndrome. Cochrane Database Syst Rev 2008; (1): CD001537
(check this in PDF content)
120
Chen MC, Lam KK, Hsu KT. Spontaneous bacterial peritonitis in adult patients with primary nephrotic syndrome. Changgeng Yi Xue Za Zhi 1999; 22(2): 227-233
(check this in PDF content)
121
Chen WC, Huang JW, Chen KY, et al. Spontaneous bilateral bacterial empyema in a patient with nephrotic syndrome. J Infect 2006; 53(3): e131-134
(check this in PDF content)
122
Lin TY, Ni YH, Chang FY, Wang NC. Cytomegalovirus pneumonitis in a patient with nephrotic syndrome receiving lowdose prednisolone and pulmonary tuberculosis. Am J Med Sci 2007; 334(5): 393-395
(check this in PDF content)
123
Anders HJ, Andersen K, Stecher B The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int 2013, 83(6): 1010-1016
(check this in PDF content)
124
Lacquaniti A, Bolignano D, Donato V, et al. Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment. Kidney Blood Press Res 2010; 33(2): 100-110
(check this in PDF content)
125
Cмиpнов АВ. Фактоpы, опpеделяющие уpовни показателей липидного обмена у больных гломеpулонефpитом без наpушения функции почек и пpи хpонической почечной недостаточности на фоне консеpвативной теpапии. Сообщение 1. Клинические фактоpы, опpеделяющие уpовень липидов и апопpотеина-В в плазме кpови и в составе низкоплотных липопpотеидов у больных гломеpулонефpитом. Hефpология 2000, 4(1) : 34-43
(check this in PDF content)
126
Anderson Sh, Komers R, BrennerBM. Chapter 26. Renal and systemic manifestations of glomerular diseases In: Brenner: Brenner and Rector’s The Kidney, 8th ed. Saunders – 2007, p 2448
(check this in PDF content)
127
Ellison DH. Wilcox ChS. Chapter 46. Diuretics In: Brenner: Brenner and Rector’s The Kidney, 8th ed. Saunders – 2007, p.1646
(check this in PDF content)
128
Смирнов АВ, Кучер АГ, Каюков ИГ, Есаян АМ. Руководство по лечебному питанию для больных хронической болезнью почек. СПб. Тверь: ООО «Издательство «Триада», 2009, 240 с
(check this in PDF content)
129
Levine JS, Iglesias J. Diuretic use and fluid management. In: Murray PT, Hall JB, Brady HR, eds: Intensive Care in Nephrology London: Taylor & Francis, 2006, 315–333
(check this in PDF content)
130
Brater DC. Update in diuretic therapy: clinical pharmacology. Semin Nephrol 2011; 31(6): 483-494
(check this in PDF content)
131
Lerma E, Berns J, Nissenson A. Current Diagnosis and Treatment Nephrology and Hypertension: The McGraw-Hill Companies, Inc. 2009, 7-21
(check this in PDF content)
132
Dorhout Mees EJ. Does it make sense to administer albumin to the patient with nephrotic oedema? Nephrol Dial Transplant 1996; 11(7): 1224-1226
(check this in PDF content)
133
Davenport A. Ultrafiltration in diuretic-resistant volume overload in nephrotic syndrome and patients with ascites due to chronic liver disease. Cardiology 2001; 96(3-4): 190-195
(check this in PDF content)
134
American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000; 106 (2 Pt 1): 362-366. [No authors listed]
(check this in PDF content)
135
Nuorti JP, Whitney CG; Prevention of pneumococcal disease among infants and children – use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59(RR-11): 1-18
(check this in PDF content)
136
Robinson J. Efficacy of pneumococcal immunization in patients with renal disease-what is the data? Am J Nephrol 2004 24(4): 402-409
(check this in PDF content)
137
Смирнов АВ, Шилов ЕМ, Добронравов ВА, Каюков ИГ, Бобкова ИН, Швецов МЮ, Цыгин АН, Шутов АМ. Национальные рекомендации. Хроническая болезнь почек:осныовные принципы скрининга, диагностики, профилактики и подходы к лечению. Нефрология 2012, 16(1): 89-115
(check this in PDF content)
138
Kaysen GA, Gambertoglio J, Jimenez I, et al. Effect of dietary protein intake on albumin homeostasis in nephrotic patients. Kidney Int 1986; 29(2): 572-577
(check this in PDF content)
139
Giordano M, De FP, Lucidi P, et al. Effects of dietary protein restriction on fibrinogen and albumin metabolism in nephrotic patients. Kidney Int 2001; 60(1): 235–242
(check this in PDF content)
140
Maroni BJ, Staffeld C, Young VR, et al. Mechanisms permitting nephrotic patients to achieve nitrogen equilibrium with a protein-restricted diet. J Clin Invest 1997, 99(10): 24792487
(check this in PDF content)
141
Mak SK, Short CD, Mallick NP. Long-term outcome of adult-onset minimal-change nephropathy. Nephrol Dial Transplant 1996; 11(11): 2192-2201
(check this in PDF content)
142
Guess A, Agrawal S, Wei CC. Dose- and time-dependent glucocorticoid receptor signaling in podocytes. Am J Physiol Renal Physiol 2010; 299(4): F845-853
(check this in PDF content)
143
Ransom RF, Lam NG, Hallett MA, et al. Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization. Kidney Int 2005; 68(6): 2473-2483
(check this in PDF content)
144
Tornatore, KM, Logue, G, Venuto, RC, Davis, PJ. Pharmacokinetics of methylprednisolone in elderly and young healthy males. J Am Geriatr Soc 1994; 42: 1118-1122
(check this in PDF content)
145
Cattran DC, Alexopoulos E, Heering P, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int 2007; 72(12): 1429-1447
(check this in PDF content)
146
Eguchi A, Takei T, Yoshida T, et al. Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome. Nephrol Dial Transplant 2010; 25(1): 124-129
(check this in PDF content)
147
Firestein GS, Budd RC, Harris ED et al. Kelley’s Textbook of Rheumatology, 9h ed., Saunders, 894-916, 941-953
(check this in PDF content)
148
Staa TP, Leufkens HG, Abenhaim Let al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000; 39(12): 1383-1389
(check this in PDF content)
149
Staa TP, Leufkens HG, Abenhaim Let al. Use of oral corticosteroids in the United Kingdom. QJM 2000; 93(2): 105-111
(check this in PDF content)
150
Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 2011; 365(1): 62-70
(check this in PDF content)
151
Cooper MS. Sensitivity of bone to glucocorticoids. Clin Sci (Lond) 2004; 107(2): 111-123
(check this in PDF content)
152
Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102(2): 274–282
(check this in PDF content)
153
Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 2000; 85: 2907–2912
(check this in PDF content)
154
Kanis, JA, Johansson, H, Oden, A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19(6): 893-899
(check this in PDF content)
155
Pranić-Kragić A, Radić M, Martinović-Kaliterna D, Radić J. Glucocorticoid induced osteoporosis. Acta Clin Croat 2011; 50(4): 563-566
(check this in PDF content)
156
Massey LK, Whiting SJ. Dietary salt, urinary calcium, and bone loss. J Bone Miner Res 1996; 11(6): 731-736
(check this in PDF content)
157
Lee CT, Lien YH, Lai LW, et al. Variations of dietary salt and fluid modulate calcium and magnesium transport in the renal distal tubule. Nephron Physiol 2012; 122(3-4): 19-27
(check this in PDF content)
158
Reginster JY, Kuntz D, Verdickt W, et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 1999; 9: 75-81
(check this in PDF content)
159
Ringe JD, Coster A, Meng T, et al. Treatment of glucocorticoidinduced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int 1999; 65: 337-340
(check this in PDF content)
160
Sambrook, P, Birmingham, J, Kelly, P, et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993; 328:1747-1752
(check this in PDF content)
161
Grieff M, Bushinsky DA. Diuretics and disorders of calcium homeostasis. Semin Nephrol 2011; 31(6): 535-541
(check this in PDF content)
162
Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006; 355(20): 2156-2157
(check this in PDF content)
163
Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83(9): 1032-1045
(check this in PDF content)
164
Staa TP, Geusens P, Zhang B, et al. Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids. Rheumatology (Oxford) 2007; 46(3): 460-466
(check this in PDF content)
165
Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001; 12(6): 1164-1172
(check this in PDF content)
166
ten Dam MA, Hilbrands LB, Wetzels JF. Nephrotic syndrome induced by pamidronate. Med Oncol 2011; 28(4): 1196-1200
(check this in PDF content)
167
Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008; 74(11): 1385-1393
(check this in PDF content)
168
Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008; 358(12): 1304-1306
(check this in PDF content)
169
Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010; 362: 1761-1771
(check this in PDF content)
170
Kim SY, Schneeweiss S, Katz JN, et al. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res 2011; 26(5): 993-1001
(check this in PDF content)
171
Kuo YJ, Tsuang FY, Sun JS, et al. Calcitonin Inhibits SDCPInduced Osteoclast Apoptosis and Increases Its Efficacy in a Rat Model of Osteoporosis. PLoS One 2012; 7(7): e40272
(check this in PDF content)
172
Khajuria DK, Razdan R, Mahapatra DR. Drugs for the management of osteoporosis: a review. Rev Bras Reumatol 2011; 51(4): 365-371, 379-382
(check this in PDF content)
173
Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoidinduced osteoporosis: thirty-six-month results of a randomized, doubleblind, controlled trial. Arthritis Rheum 2009; 60: 3346–3355
(check this in PDF content)
174
Gallay PA. Cyclophilin inhibitors. Clin Liver Dis 2009; 13(3): 403-417
(check this in PDF content)
175
Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008; 14: 931-938
(check this in PDF content)
176
Mathieson PW. Proteinuria and immunity – an overstated relationship? N Engl J Med 2008; 359 (23): 2492-2494
(check this in PDF content)
177
Mathieson PW. Podocyte actin in health, disease and treatment. Nephrol Dial Transplant 2010; 25 (6): 1772-1773
(check this in PDF content)
178
Yanagida- Asanuma E, Asanuma K, Kim K, et al. Synaptopodin protects against proteinuria by disrupting Cdc42: IRSp53: Mena signaling complexes in kidney podocytes. Am J Pathol 2007; 171 (2): 415-427
(check this in PDF content)
179
Asanuma K, Kim K, Oh J, et al. Synaptopodin regulates the actin- bundling activity of alpha-actinin in an isoform- specific manner. J Clin Invest 2005; 115 (5): 1188-1198
(check this in PDF content)
180
Asanuma K, Yanagida-Asanuma E, Faul C et al. Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat Cell Biol 2006; 8 (5): 485-491
(check this in PDF content)
181
Смирнов АВ, Трофименко ИИ. Практические вопросы применения циклоспорина в лечении гломерулопатий. Нефрология 2010; 14(4): 96-102
(check this in PDF content)
182
Nashan B, Cole E, Levy G, Thervet E, Clinical validation studies of neoral C2 monitoring: a review. Transplantation 2002; 73 [Suppl. 9]: S3—S11
(check this in PDF content)
183
Levy G, Thervet E, Lake J, Uchida K. Patient management by Neoral C2 monitoring: An international consensus statement. Transplantation 2002; 73 [Suppl.9]: S12—S18
(check this in PDF content)
184
Cole E, Midtvedt K, Johnston A, et al. Recommendations for the Implementation of Neoral C2 Monitoring in Transplantation. Clinical Practice 2002; 73 [ Suppl.9], S19—S22
(check this in PDF content)
185
Вознесенская Т С Эффективность и токсичность циклоспорина А. Мониторинг концентрации. Обзор литературы. Нефрология и диализ 2005; 7(2): 135-149
(check this in PDF content)
186
Nakamura T, Nozu K, Iijima K, et al. Association of cumulative cyclosporine dose with its irreversible nephrotoxicity in Japanese patients with pediatric-onset autoimmune diseases. Biol Pharm Bull 2007; 30(12): 2371-2375
(check this in PDF content)
187
Naito M, Takei T, Eguchi A, et al. Monitoring of blood cyclosporine concentration in steroid-resistant nephrotic syndrome. Intern Med 2008; 47(18): 1567-1572
(check this in PDF content)
188
Meyrier, A. Treatment of idiopathic nephrosis by immunophillin modulation. Nephrol Dial Transplant 2003; 18[Suppl 6]:vi79- vi 86
(check this in PDF content)
189
Meyrier, A, Noël, LH, Auriche, P, Callard, P. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Société de Néphrologie. Kidney Int 1994; 45: 1446 -1456
(check this in PDF content)
190
Alexopoulos E, Papagianni A, Tsamelashvili M et al. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant 2006; 21 (11): 3127-3132
(check this in PDF content)
191
Ponticelli C. Cyclosporine: from renal transplantation to autoimmune diseases. Ann N Y Acad Sci 2005 1051: 551–558
(check this in PDF content)
192
Moroni G, Doria A, Ponticelli C.Cyclosporine (CsA) in lupus nephritis: assessing the evidence. Nephrol Dial Transplant 2009; 24(1): 15-20
(check this in PDF content)
193
El-Husseini A, El-Basuony F, Donia A, et al. Concomitant administration of cyclosporine and ketoconazole in idiopathic nephrotic syndrome. Nephrol Dial Transplant 2004 ;19(9): 2266-2271
(check this in PDF content)
194
Shannon MW, Borron SW, Burns M. Haddad and Winchester’s Clinical Management of Poisoning and Drug Overdose, Chapter 57 – Transplant Agents and Other Immunosuppressives 4th ed. Saunders; 2007; 943-948
(check this in PDF content)
195
Клим Ф. Такролимус при трансплантации почки. Сообщение I, Нефрология 2007; 11 (2): 7-25
(check this in PDF content)
196
Sinha MD, Macleod R, Rigby E, et al. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant 2006; 21: 1848-1854
(check this in PDF content)
197
Gulati S, Prasad N, Sharma RK, et al. Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant 2008 ;23(3): 910-913
(check this in PDF content)
198
Li X, Li H, Ye H, et al. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. Am J Kidney Dis 2009; 54(1): 51-58
(check this in PDF content)
199
Li X, Li H, Chen J, et al. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome. Nephrol Dial Transplant 2008; 23(6): 1919-1925
(check this in PDF content)
200
Li X, Xu N, Li H, et al. Tacrolimus as rescue therapy for adult-onset refractory minimal change nephrotic syndrome with reversible acute renal failure. Nephrol Dial Transplant 2013; 28(9):2306-2312
(check this in PDF content)
201
Fan L, Liu Q, Liao Y, et al. Tacrolimus is an alternative therapy option for the treatment of adult steroid-resistant nephrotic syndrome: a prospective, multicenter clinical trial. Int Urol Nephrol 2012; 45(2): 459-468
(check this in PDF content)
202
Ponticelli C, Edefonti A, Ghio L, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant 1993; 8: 1326-1332
(check this in PDF content)
203
Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14 [Suppl 1]: s2-8
(check this in PDF content)
204
Siu YP, Tong MK, Leung K, et al. The use of enteric-coated mycophenolate sodium in the treatment of relapsing and steroiddependent minimal change disease J Nephrol 2008; 21: 127 – 131
(check this in PDF content)
205
Choi MJ, Eustace JA, Gimenez LF et al. Mycophenolate mofetil treatment for primary glomerular disease. Kidney Int 2002; 61: 1098–1114
(check this in PDF content)
206
Pesavento TE, Bay WH,Agarwal G, et al. Mycophenolate therapy in frequently relapsing minimal change disease that has failed cyclophosphamide therapy. Am J Kidney Dis 2004; 43(3): e3-6
(check this in PDF content)
207
Segarra A, Amoedo ML, Martinez Garcia JM, et al. Efficacy and safety of ‘rescue therapy’with mycophenolate mofetil in resistant primary glomerulonephritis- a multicentre study. Nephrol Dial Transplant 2007; 22: 1351-1360
(check this in PDF content)
208
Yi ZW, Dang XQ, He QN, et al. Assessment of mycophenolate mofetil for treatment of frequently relapsing nephrotic syndrome in children. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2007; 32(6): 938-940
(check this in PDF content)
209
François H, Daugas E, Bensman A, Ronco P. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis 2007; 49(1): 158-161
(check this in PDF content)
210
Kurosu N, Sugiura H, Iwasaki C, et al. Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome. Intern Med 2009; 48(21): 1901-1904
(check this in PDF content)
211
Hoxha E, Stahl RA, Harendza S. Rituximab in adult patients with immunosuppressive-dependent minimal change disease. Clin Nephrol 2011; 76(2): 151-158
(check this in PDF content)
212
Gulati A, Sinha A, Jordan SC, et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 2010; 5(12): 2207-2212
(check this in PDF content)
213
Peters HP, van de Kar NC, Wetzels JF. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature. Neth J Med 2008; 66(10): 408-415
(check this in PDF content)
214
Ravani P, Ponticelli A, Siciliano C, et al. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 2013; 84(5): 1025-1033
(check this in PDF content)
215
Magnasco A, Ravani P, Edefonti A, et al. Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 2012; 23(6): 1117-1124
(check this in PDF content)
216
Bruchfeld A, Benedek S, Hilderman M, et al. Rituximab for minimal change disease in adults: long-term follow-up. Nephrol Dial Transplant first published online October 11, 2013
(check this in PDF content)
217
Kronbichler A, König P, Busch M, et al. Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases. Wien Klin Wochenschr 2013;1 25(11-12): 328-333
(check this in PDF content)
218
Munyentwali H, Bouachi K, Audard V, et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int 2013; 83(3): 511-516
(check this in PDF content)
219
Cara-Fuentes G, Kairalla JA, Ishimoto T, et al. Rituximab in idiopathic nephrotic syndrome: does it make sense? Pediatr Nephrol 2013 Jun 23. [Epub ahead of print].
(check this in PDF content)
220
Bruneau S, Dantal J. New insights into the pathophysiology of idiopathic nephrotic syndrome. Clin Immunol 2009; 133(1): 13-21
(check this in PDF content)
221
Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011; 3(85): 85ra46
(check this in PDF content)
222
Cade R, Mars D, Privette M, et al. Effect of long-term azathioprine administration in adults with minimal-change glomerulonephritis and nephrotic syndrome resistant to corticosteroids. Arch Intern Med 1986; 146: 737–741 Авторы заявляют об отсутствии конфликта
(check this in PDF content)